ImCheck

formerly Imcheck TherapeuticsAcquired

Imchecktherapeutics.com

Marseille, France · Founded 2015 · $174.1M raised

Headquarters
Marseille
Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$174.1M
Last Round
$103.0M Series CJun 2022
Rounds
4
Acquisition Date
Oct 2025

About

ImCheck Therapeutics is a clinical-stage biotech pioneering immunomodulation through the butyrophilin (BTN) and BTN-like (BTNL) checkpoint molecule superfamily. The company designs next-generation immunotherapeutic antibodies targeting cancer, infectious disease, and autoimmune conditions. ImCheck was acquired by Ipsen in 2025 to expand its oncology pipeline.

Summary

ImCheck is a Biotech company based in Marseille, France, founded in 2015. It has raised $174.1M in total across 4 rounds, most recently a $103.0M Series C round in Jun 2022. Investors include Ipsen.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionOct 2025

Sign up to see all 5 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ImCheck on Indexed.vc
<a href="https://indexed.vc/companies/imcheck"><img src="https://indexed.vc/api/badge/company/imcheck" alt="ImCheck on Indexed.vc" width="260" height="76" /></a>